| answer text |
<p>The Global Antimicrobial Resistance (AMR) Innovation Fund is a £50 million investment
over five years to tackle AMR, with the aim of attracting significant additional investment
internationally to stimulate global research. It is not looking at reimbursement models
to incentivise the development of new classes of antibiotics or planning to fund pilots
at this stage.</p><p>Domestically, the Department is working with the National Institute
for Health and Care Excellence and the Association of the British Pharmaceutical Industry
to develop a new reimbursement model for antimicrobials, and has secured broad agreement
to principles that would permit a model to ‘de-link’ company revenues from sales.
The aim of this work is to support good antimicrobial stewardship. Discussions with
a number of leading pharmaceutical companies have highlighted challenges in evaluating
antimicrobial medicines, and the Department is working closely with industry partners
to address these.</p>
|
 |
